53636-56-9

Usage

Uses

Used in Organic Synthesis:
Methyl 3-bromopicolinate is utilized as a building block in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of novel and effective products in these industries.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
In the field of organic chemistry, methyl 3-bromopicolinate serves as a crucial reagent in Suzuki-Miyaura cross-coupling reactions. These reactions are instrumental in the production of complex organic molecules, highlighting the compound's significance in creating advanced chemical structures with diverse applications.

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)6-5(8)3-2-4-9-6/h2-4H,1H3

Upstream product

• 30683-23-9 3-bromopicolinic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 1049093-85-7 3-bromopicolinoyl chloride 
• 124-41-4 sodium methylate 
• 55758-02-6 3-bromopyridine-2-carbonitrile 
• 101752-05-0 methanol hydrochloride 
• 188677-47-6 3-Bromo-pyridine-2-carboxylic acid phenylamide 
• 10354-53-7 N-phenylpicolinamide 

Downstream Products

• 174681-89-1 methyl 3-Phenylpyridine-2-carboxylate 
• 54112-52-6 3-(4-methoxy-benzylsulfanyl)-pyridine-2-carboxylic acid 
• 73776-20-2 8-hydroxyquinoline-7-carboxylic acid methyl ester 
• 219623-05-9 3-ethynylpicolinic acid 
• 174681-86-8 methyl 3-vinylpicolinate 
• 878805-23-3 3-cyclopropylpyridine-2-carboxylic acid 
• 1240594-87-9 2-(3-bromopyridin-2-yl)propan-2-ol 
• 1609572-11-3 tert-butyl 7-oxo-6-(2-oxo-2-phenylethyl)-5,6-dihydrocyclopenta[b]pyridine-6-carboxylate 
• 1439933-38-6 (S)-methyl 3-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)picolinate 
• 1422169-65-0 methyl 3-(5-(2-(benzyloxy)-2-oxoethyl)benzofuran-2-yl)picolinate 
• 1309878-86-1 methyl 3-[3-(4-methoxybenzylsulfanyl)pyridin-2-yl]-3-oxo-2-(2-trifluoromethylphenyl)propionate 
• 1231756-37-8 methyl 3-(3-mercaptopyridin-2-yl)-3-oxo-2-(2-trifluoromethylphenyl)propionate 
• 53636-57-0 methyl 3-(4-methoxyphenylmethylthio)pyridine-2-carboxylate 
• 1186038-19-6 5-(3-chlorophenylamino)benzo[f][1,7]naphthyridine-8-carboxylic acid 

Relevant academic research and scientific papers

Palladium NNC Pincer Complex as an Efficient Catalyst for the Cycloisomerization of Alkynoic Acids

A two-step (nucleophilic substitution/palladation by oxidative addition) sequence provides a high-yielding access to a non-symmetrical palladium NNC pincer complex. A number of terminal and internal alkynoic acids with different substitution patterns at the α- and β-positions are regio- and diastereoselectively cycloisomerized to the corresponding exocyclic enol lactones in the presence of exceedingly low amounts of the latter palladium complex, so that unprecedented turnover numbers and frequencies ranging from 1,000,000 to 700,000 and from 41,667 to 9722 h?1, respectively, are achieved. The optimized protocol, based on the use of a catalytic amount of triethylamine as base, allows an easy real-time monitoring of the reaction by NMR spectroscopy. Several pieces of evidence in favor of the direct participation of the above pincer complex as the catalyst of the reaction have been gathered from kinetic and poisoning experiments. (Figure presented.).

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Synthesis of regioisomeric pyrido[c]azocanones from azaindanone derivatives

A ring enlargement reaction with methylamine gave new pyrido[2,3-c]-, pyrido[3,4-c]- and pyrido[3,2-c]azocanone derivatives from cyclic β-oxo esters with a cyclopentapyridine skeleton and a 1,4-diketone moiety. The starting materials for this ring transformation were either prepared from halogenopyridine carboxylates by Heck reaction and subsequent hydrogenation, or (halogenomethyl)pyridine carboxylates were submitted to SN reaction with diethyl malonate. Both routes were completed by Dieckmann condensation to build the cyclic β-oxo ester structure and alkylation with phenacylbromide to install the 1,4-diketone motif. Copyright

1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS

The invention relates to compounds of formula I: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof

The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R1, R2, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[ c ][2,6]naphthyridine-8- carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the Treatment of Cancer

Herein we chronicle the discovery of CX-4945 (25n), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clinical trials for cancer. CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting prosurvival and antiapoptotic pathways. These biological properties as well as the suitability of CK2s small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer. The optimization leading to 25n (Ki = 0.38 nM) was guided by molecular modeling, suggesting a strong binding of 25n resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. 25n was found to be highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models. The discovery of 25n will allow the therapeutic targeting of CK2 in humans for the first time.

GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE

The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.

PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES

The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceut

An intra/intermolecular suzuki sequence to benzopyridyloxepines containing geometrically pure exocyclic tetrasubstituted alkenes

(Chemical Equation Presented) A route to enable the preparation of 5-benzylidenyl-benzopyridyloxepine analogues was developed to continue our research in the field of nuclear hormone receptor modulators. The key steps are1) a syn-stereoselective diboratio

CYCLOALKANOPYRIDINE DERIVATIVE

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.